Program Information

Activity Information

Fairmont Sonoma Mission Inn & Spa
100 Boyes Blvd,
Sonoma, CA 95476
June 28-30, 2024

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology and the California Society of Allergy, Asthma & Immunology. The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement: The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

CBRN Designation: The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 10.5 contact hours.

Learning Objectives

At the end of this activity, participants should be able to:

  • OIT:
    • Review clinical data on the efficacy and safety of allergen immunotherapy
      Determine the optimal regimen and duration of allergen Immunotherapy
  • Asthma Biologics:
    • Evaluate and select evolving therapeutic strategies
    • Review mechanisms, current biologics, and effects
    • Evaluate current clinical data indicating suggesting possible remitted effects of biologics in asthma
  • Food Allergy:
    • Select appropriate patients for an oral food challenge
    • Identify safety precautions necessary for conducting oral food challenge
    • Describe recent advances in OIT, SLIT, and EPIT
    • Identify the advantages and disadvantages of all methods of treatment
    • Be prepared to discuss advances, expectations, and limitations with your food-allergic patients
  • Immunodeficiency:
    • Describe the cardinal manifestations of immune deficiencies and how to distinguish these immune defects.
    • Determine the infectious and non-infectious complications of immune deficiencies and the laboratory measures and genetic studies that can dissect these issues.
    • Assess the effects of immune globulin therapies on immunologic systems
    • Review the pathophysiologic mechanisms underlying innate immunity defects
  • CVID:
    • Attendees will make the earliest possible diagnosis for patients with CVID based on clinical, genetic and other features, and use a patient-centered approach that incorporates each patient’s goals and values to select appropriate treatment.
    • Describe an approach to clinically evaluate CVID, including clinical, genetic, and other features.
    • Use clinical, laboratory, and genetic features to formulate a treatment regimen for CVID that addresses the disease’s immune deficiency and immune dysregulation features.

Target Audience

Practicing allergists and allied health care providers in the field of allergy and immunology.

Joint Providership

Jointly Provided by the American College of Allergy, Asthma & Immunology and the California Society of Allergy, Asthma, and Immunology.

Program Agenda

Disclosure Policy

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Examples of such organizations include advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers.

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Satellite Activities

Industry-led lectures and exhibits will be conducted as optional learning opportunities in conjunction with this event. These optional activities are not certified for CME credit and are not planned or sanctioned by the California Society of Allergy, Asthma, and Immunology.

Planning Committee

The committee includes the following LanAnh Do, MD, Barbara Ariue, MD, Sonal R. Patel, MD, Raffi Tachdjian, MD, MPH, Javed Sheikh, MD, Myngoc Nguyen, MD, Sheila M. Bonilla, MD, Suzanne Teuber, MD

ADA Statement

In compliance with the Americans with Disabilities Act, AAIFNC requests that any participant in need of accommodation send email to: email@csaai.org